IMMUNOTHERAPY Specific immunotherapy (SI) consists of manipulating the individual’s immune system in order to modify its response to the allergen (immunomodulation). With regard to allergic diseases, SI has been used as a therapeutic resource for controlling and reducing symptoms for approximately 90 years. Patients with mild or moderate asthma and a proven IgE mechanism who have not benefited from strict environmental control and pharmacological treatment alone are candidates for SI. PHARMACOLOGICAL TREATMENT The regimen described below is proposed by the III Brazilian Consensus on Asthma Management. Drugs can be classified into two categories, according to the purpose of their use:
- cover mattresses and pillows with dust mite-proof covers (covers must be washable); carefully vacuum the mattress, pillow, around the base of the bed and the bedroom floor weekly;
- avoid using brooms and dusters; clean all surfaces in the room weekly with a damp cloth, including the valances to which curtains are attached, the window sills and the tops of cabinets;
- Dehumidifiers help control relative humidity, but they can dry out the environment too much, causing irritating coughing fits and worsening asthma attacks; vaporizers are contraindicated in rooms of allergy sufferers as they facilitate the proliferation of fungi;
- remove feather and/or kapok pillows, wool blankets and down comforters, replacing them with synthetic fabric ones and washing them weekly;
- avoid rugs, carpets and curtains; give preference to washable floors and blinds, or materials that can be cleaned with a damp cloth;
- avoid objects that accumulate dust (stuffed animals, boxes, magazines, books, suitcases, pillows, etc.);
- avoid mold and humidity: 3% to 5% carbolic acid solution (or bleach) can be applied to moldy areas until the cause of the humidity is definitively resolved, however, these are volatile products with a strong odor that can cause irritation to the airways, therefore their application should not be done by the patient, and the house must be kept ventilated for 6 hours before residents enter;
- avoid keeping furry animals inside the home; if this is not possible, they should be bathed at least once a week, but they should not, under any circumstances, remain in the bedroom;
- avoid the use of talcum powders, perfumes, disinfectants and cleaning products with strong odors; insecticides released by heating, despite having no odor, are irritating to the respiratory mucosa;
- keep the house free of insects (especially cockroaches), avoiding the accumulation of dirt, old paper or food remains;
- prohibit active smoking inside the home and always discourage it among adolescents.
Treatment of mild asthma should be limited to acute exacerbations with the use of a short-acting β2 agonist via inhaler. In adolescents with exercise-induced asthma, prior use of a short-acting β2 agonist may be indicated up to 15 minutes to half an hour before exercise. The use of cromones, antileukotrienes and long-acting β2 agonists is also an option. Anti -inflammatory agents are recommended for patients with moderate asthma. Undoubtedly, corticosteroids are the main anti-inflammatory agents and their action is observed quickly, unlike what occurs with other drugs. However, the possibility of side effects resulting from their use makes it necessary to monitor these patients more closely and frequently. In these cases, an inhaled short-acting β2 agonist can be used to relieve symptoms when necessary (maximum four times/day), or a long-acting β2 agonist. The treatment regimen with inhaled corticosteroids (metered-dose aerosol and dry powder inhaler) should be initiated, but the patient should be reassessed in four to six weeks. If the patient improves, the long-acting β2-agonist should be discontinued, reducing the dose of the inhaled corticosteroid. In the case of severe asthma, oral corticosteroids should be used for a short period of time. If prolonged use is necessary, an alternate-day regimen or one in which the lowest dose capable of establishing control is maintained should be preferred. Once control is achieved, the oral corticosteroid should be discontinued and the withdrawal of other medications should follow the same steps as for the treatment of moderate asthma. The initial dose of inhaled corticosteroids to be administered ranges from 500 µg to 1,000 µg of beclomethasone dipropionate/day (or equivalent). The use of a spacer followed by oral hygiene is recommended to eliminate beclomethasone dipropionate deposited in the oropharynx. Leukotriene antagonists have been suggested as alternative drugs for these patients because they allow for a reduction in the need for corticosteroids, or when the patient cannot use these medications for long periods. Asthmatic adolescents, like any patient with a chronic disease, should have regular checkups to monitor the correct use of medications, as well as to assess their growth and development. Respiratory function tests are recommended. Other important topics include assessing school readiness, sociability, encouraging the practice of sports, and maintaining quality of life. Ongoing anti-smoking campaigns aimed at the patient and their family members are also welcome, and consideration should be given to the cost/benefit of pets. A global view of the patient is part of providing welcoming and efficient care, and the multidisciplinary team should be aware of all this diversity. ACKNOWLEDGMENTS To the entire team at the Center for Studies on Adolescent Health (NESA) for their constant collaboration.
- to improve acute symptoms (rapid onset β2-agonist, ipratropium bromide and aminophylline);
- to prevent symptoms for the maintenance phase (inhaled and systemic corticosteroids, cromones, long-acting β2-agonist and slow-release theophylline).
Rua da Conceição, 100, Centro, Niterói, RJ, Postal Code: 24020-085, Brazil.
revista@adolescenciaesaude.com